The relationship between high-fat dairy consumption and obesity, cardiovascular, and metabolic disease
The study, A Study of Tirzepatide in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5), has the primary outcome of percent weight change from baseline in body weight over a 72-week period
SELECT Trial Semaglutide and Cardiovascular Outcomes (NEJM, 2023): 20% reduction in major adverse cardiovascular events with Wegovy in overweight/obesity
What Happens to Price And What That Means for Patients The price erosion data is where this story gets truly consequential
Patients should be educated about recognising and managing hypoglycaemic episodes, including keeping fast-acting carbohydrates readily available
In a published phase 2 trial, Retatrutide was studied over 24 and 48 weeks